based on data from retrospective analyses showing an association between ACT values and thrombotic 5,6 or bleeding 7 outcomes. However, these observational studies are subject to confounding, and they were conducted before the availability of modern antiplatelet therapy and, for some studies, before the widespread use of coronary stents. Conversely, more recent analyses have found no association between ACT and the risks of bleeding 8 or thrombotic 9,10 events. Whether ACT is correlated with periprocedural thrombotic or bleeding events in the modern era of PCI remains unclear.
P eriprocedural anticoagulation is recommended during percutaneous coronary intervention (PCI) to prevent thrombus forming on the wires, balloon, and catheters. 1 Unfractionated heparin (UFH) remains widely used in this indication (≈60% of patients with non-ST-segment-elevation myocardial infarction [NSTEMI] undergoing PCI in the United States received UFH, according to data from the recent National Cardiovascular Data Registry). 2 Because UFH has a narrow therapeutic window and its effect is poorly predictable, 3 guidelines from the United States recommend UFH dosing guided by measurement of activated clotting time (ACT) in the catheterization laboratory. 4 This recommendation is ACT Predicts Efficacy of UFH During PCI The Fondaparinux With Unfractionated Heparin During Revascularization in Acute Coronary Syndromes (FUTURA/ OASIS-8) trial (clinicaltrials.gov Identifier: NCT00790907) randomized patients with high-risk non-ST-segment-elevation acute coronary syndromes (NSTE-ACS) treated with 2.5 mg fondaparinux subcutaneously once daily and undergoing PCI to low-dose UFH or to standard-dose UFH with ACT guidance. 11, 12 This was the first trial to compare UFH dosing in the modern era of PCI. The trial showed no difference between regimens in terms of the composite primary outcome (48-hour major or minor bleeding or vascular complications): 4.7% in the low-dose group versus 5.8% in the standard-dose group (odds ratio [OR], 0.80; 95% confidence interval [CI], 0.54-1.19; P=0.27), but with a trend toward higher rates of thrombotic outcomes (composite of death, myocardial infarction [MI] , or target vessel revascularization [TVR]) with lowdose UFH (4.5% versus 2.9%; OR, 1.58; 95% CI, 0.98-2.53; P=0.06).
As the FUTURA/OASIS-8 trial compared 2 different heparin regimens, the additional value of ACT guidance remains unclear. The aims of the present analysis were therefore to determine the relationship between the UFH dose administered and the peak ACT and to determine the association between peak ACT value and thrombotic and bleeding outcomes in patients with NSTE-ACS undergoing PCI.
Methods
The FUTURA/OASIS-8 trial included 2026 patients. The study was reviewed and approved by ethical committees or institutional review boards at each participating site in accordance with national and international regulations. Each participant provided written informed consent before enrollment. Enrollment had to be performed within 48 hours of the most recent symptoms.
Patients randomized to the standard-dose group received an initial UFH bolus dose of 85 U/kg (with a maximum of 10 000 U), with an additional bolus if needed to achieve a target ACT of 300 to 350 s according to the Hemochron device (International Technidyne Corp, Edison, NJ) or 250 to 300 s according to the Hemotech device (Medtronic Hemotech, Englewood, CO). For patients with planned use of glycoprotein (GP) IIb/IIIa inhibitors, the UFH dose was 60 IU/ kg, with an additional bolus to achieve a target ACT ≥200 s (using either device). In the event of a prolonged PCI procedure (exceeding 1 hour), an additional bolus of UFH guided by ACT was authorized.
Patients randomized to the low-dose group received a fixed UFH dose bolus of 50 IU/kg irrespective of planned GP IIb/IIIa inhibitor use.
ACT measurements were performed in both groups ≈5 minutes after administration of the initial bolus by an unblinded study coordinator who kept the operator and the rest of the study team blinded to the ACT results with the use of sham boluses in the fixed low-dose arm. Up to 2 additional bolus doses could be administered according to an ACT dosing algorithm ( Figure I in the Data Supplement). The PCI procedure was performed according to the investigator's routine practice.
Of 2026 patients enrolled into the FUTURA/OASIS-8 trial, 1904 patients underwent PCI and had ACT measurements taken. ACT was measured using the Hemochron device in 1882 patients, the Hemotech device in 18 patients, and other devices in 4 patients. The study sample comprises the 1882 patients in whom the ACT measurements were taken with the Hemochron device.
Outcomes
Peri-PCI was defined as the time from randomization to 48 hours post PCI procedure. Bleeding definitions were specific to the trial and have been described previously. 12 Major bleeding included overt bleeding with at least one of the following: fatal bleeding, symptomatic intracerebral hemorrhage, intraocular bleeding leading to significant vision loss, bleeding requiring surgical intervention, hemoglobin drop of ≥3 g/dL or bleeding requiring transfusion of ≥2 U of packed red blood cells or equivalent whole blood. Minor bleeding included any other significant bleeding not meeting the definition for major bleeding and leading to discontinuation of any antithrombotic medication or transfusion of 1 U of blood (whole blood or packed red blood cells).
Major PCI-related procedural complications were defined as abrupt vessel closure, new angiographic filling defect representing either angiographic thrombus or major dissection with reduced flow, no-reflow phenomenon, or catheter-related thrombosis. Stent thrombosis was defined according to the Academic Research Consortium. 13 Major vascular access site complications included large hematoma, pseudoaneurysm requiring treatment, arteriovenous fistula, and other vascular procedures related to the access site.
Statistical Analysis
Analyses were performed using SAS version 9.2 (SAS Institute, Cary, NC). Baseline patient and procedure characteristics are presented in categories of peak ACT by 50-s increments >200 s. Continuous data are summarized by means and SDs. Correlation coefficients between peak ACT and UFH dose were calculated using Spearman's rank correlation coefficient. Logistic modeling was used to identify ORs and 95% CIs for the effects of peak ACT on outcomes by fitting a restricted cubic spline function with knots at the 5th, 35th, 65th, and 95th percentiles. Group median was chosen as the reference group for all spline plots. The peak ACT was categorized using cut points from 200 to 350 s with 10-s increments. Logistic modeling was used to identify ORs and 95% CIs for the effects of peak ACT on outcomes. To reduce small sample bias, the ORs and P values comparing ACT above versus below all cut points on the outcome of death/MI/TVR and peri-PCI major/minor bleeding/major vascular access site complication were calculated using the penalized likelihood estimation. 14 The cut point corresponding to the smallest P value was identified as the threshold. Multivariable logistic models on death/MI/TVR were adjusted for age, sex, diabetes mellitus, prior PCI, creatinine concentration, systolic blood pressure, elevated biomarker at presentation, and heart failure. For bleeding complications, radial access was also added to the model. Sensitivity analysis was performed in patients with or without planned GP IIb/IIIa inhibitor use. A 2-tailed P<0.05 was considered statistically significant.
Results
Among the 1882 patients in whom ACT was performed with the Hemochron device, 73 (3. The initial bolus of UFH achieved a median ACT of 268 s (Q1-Q3, 231-315) in the low-dose arm and 318 s (Q1-Q3, 271-368) in the standard-dose arm. In the standard-dose arm, 21.9% of the patients required additional boluses of UFH to 
Thienopyridine loading dose in catheterization laboratory 176 (9) 5 (7) 25 (8) 35 (8) 64 (13) 47 (8) Clopidogrel 176 (9) 5 (7) 25 (8) 35 (8) 64 (13) 47 (8) Ticlopidine In the standard-dose group, where heparin dosing was guided by ACT, 86.9% (606/707) of the patients not receiving planned GP IIb/IIIa inhibitors reached the target range (ACT≥300 s) versus 99.5% (219/220) of those in whom GP IIb/IIIa inhibitor use was planned (target ACT≥200 s).
Patient's baseline characteristics according to ACT categories are detailed in Table 1 and outcomes in Table 2 .
Correlation Between UFH Dose and ACT
There was a weak correlation between peak ACT and all of the UFH doses analyzed: for the initial UFH dose (that administered after randomization), r=0.38; for the initial+bolus UFH dose (initial dose+additional bolus, as required, to reach the target ACT), r=0.35; for the total study UFH dose (initial bolus+additional bolus to reach target ACT+additional boluses in case of a prolonged procedure), r=0.34; and for all UFH doses (total study UFH+nonstudy UFH, as some nonstudy heparin may have been administered in the event of complications), r=0.34.
Outcomes According to ACT as a Linear Function
Spline curves of ACT with ischemic and bleeding outcomes shown in Figures 1 and 2 show no linear or nonlinear relationship between ACT and outcomes except in patients without planned GP IIb/IIIa inhibitors, in which a nonlinear relationship between ACT and thrombotic complications was demonstrated (test for curvature P=0.042).
Outcomes According to ACT as a Threshold
To determine whether there was a threshold of ACT below which the risk of an adverse outcome was increased, the population was divided into 2 groups, 1 below and 1 above a given cut point of ACT. The cut point was then modified into 10-s increments, and a minimum P value approach was performed. In the global population, for thrombotic outcomes (death/MI/ TVR), the cut point with the lowest P value was 220 s (3.2% in patients with ACT≥220 s versus 7.4% in patients with ACT<220 s; adjusted OR, 2.42; 95% CI, 1.25-4.39; Table I in the Data Supplement).
No GP IIb/IIIa Inhibitors
For patients with no planned use of GP IIb/IIIa inhibitors, the lowest P value cut point was also 220 s (thrombotic event rate: 8.94% versus 3.12%; adjusted OR, 3.12; 95% CI, 1.50-6.04), with cut points being consistently significant for ACT≤300 s (4.86% versus 2.78%; adjusted OR, 1.84; 95% CI, 1.06-3.21; P=0.03). For bleeding, there appeared to be no threshold ACT associated with increased bleeding ( Table II in the Data  Supplement) .
Planned GP IIb/IIIa Inhibitors
In the subgroup of patients with planned GP IIb/IIIa inhibitor use, no threshold effect was observed between 200 and (7) 37 (7) Values are n (%). MI indicates myocardial infarction; MVASC, major vascular access site complication; PCI, percutaneous coronary intervention; and TVR, target vessel revascularization.
*Including large hematoma, pseudoaneurysm requiring treatment, arteriovenous fistula, and other vascular procedures related to the access site.
†Defined as abrupt vessel closure, new angiographic filling defect representing either angiographic thrombus or major dissection with reduced flow, no-reflow phenomenon, or catheter-related thrombosis. ACT Predicts Efficacy of UFH During PCI 300 s for ischemic events or bleeding. Adjustment for baseline characteristics did not change these observations (Table 3 ; Table II in the Data Supplement). However, few events were observed in that subgroup (16 thrombotic and 24 hemorrhagic complications).
Discussion
In this analysis of a large contemporary randomized trial of patients with NSTEMI treated by PCI, patients treated with UFH monotherapy who had ACT≤300s had significantly higher rates of ischemic events. However, ACT did not predict bleeding. In contrast, no relationship between ACT and ischemic events was observed in patients treated with planned GP IIb/IIIa inhibitors.
The value of using ACT to guide UFH dosing in patients undergoing PCI is debated. Retrospective analyses using data from clinical trials from the prestent era, where the dose of UFH was left to operator discretion, had shown a clear inverse relation between ACT value and thrombotic outcomes. 5 However, because those analyses were performed, the risk of periprocedural thrombotic complications associated with PCI has decreased dramatically with the routine use of stents, procedural improvements, and the use of potent adjunctive antiplatelet therapies. In parallel, bleeding complications are strongly associated with worse outcomes in acute coronary syndromes, 15 and the ACT literature has shifted from the prediction of thrombotic events to the prediction of both thrombotic and hemorrhagic events.
A pooled analysis of 6 randomized trials 6 totaling 5216 patients indicated that an ACT value between 350 and 375 s was associated with the fewest thrombotic events and an ACT between 325 and 350 s with fewer bleeding events. More recently, a pooled analysis of 8369 patients 9 reported no correlation between ACT value and thrombotic events and a weak correlation between ACT value and hemorrhagic complications. Finally, a recent analysis from the Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) trial 10 reported that in patients with ST-segment-elevation MI (STEMI), peak procedural ACT does not have a substantial relationship with major bleeding, mortality, or major adverse cardiovascular events, although a lower peak ACT was associated with fewer cases of minor bleeding.
Given these contradictory data, guidelines are inconsistent about routine ACT measurement. The European Society of Cardiology NSTE-ACS guidelines 16 mention the possibility of using ACT to guide dosing during PCI, but do not provide a clear level of recommendation. The European Society of Cardiology revascularization guidelines mention that ACT can be used, 1 again without providing a clear level of recommendation and evidence grade. The American College of Cardiology/American Heart Association guidelines on STEMI favor systematic ACT measurement and recommend a given dosage of heparin to achieve therapeutic ACT (using 4 Our observations confirm the value of ACT guidance in modern NSTEMI PCI in patients without planned GP IIb/IIIa inhibitors with a target ACT>300 s using the Hemochron device; however, they do not confirm the role of ACT guidance in patients receiving planned GP IIb/IIIa inhibitors. The fact that ACT does not predict ischemic events in patients with GP IIb/IIIa inhibitors may be because of the fact that GP IIb/IIIa inhibitors, by reducing the rate of ischemic complications, reduce the power of the analysis. Moreover, interpretation of the results in the subgroup of patients with GP IIb/IIIa inhibitors should be done cautiously given the small sample size and the limited number of events (16 thrombotic and 24 hemorrhagic complications) in that subgroup. We did not observe any relationship between ACT and hemorrhagic complications. This observation is consistent with a recent analysis performed in patients undergoing transradial PCI. 8 Several hypotheses can be put forward to explain this finding. First, the main site of hemorrhagic complications after PCI is the access site. Because a substantial percentage of patients (more than one third) underwent the procedure via radial access, this is likely to have decreased the power of the analysis. Second, anticoagulation is briefly given for PCI as a single bolus. It is possible that with such a short duration of anticoagulation, bleeding complications appear at much higher ACT levels than would be the case with prolonged anticoagulation. Finally, the ACT measurement may not be sensitive enough to predict bleeding. The FUTURA/OASIS-8 trial is the only study to date where ACT guidance forms part of a randomized algorithm, which represents a key methodological strength to avoid bias. The present analysis is the largest data set to date from a single randomized trial with systematic ACT performed: Rozenman et al 10 included 1624 patients with STEMI; and Bertrand et al 8 included 1234 patients from a registry and analyzed ACT at the end of the procedure and not peak ACT.
The global results of the FUTURA/OASIS-8 trial reinforce our observations: no difference was observed in the primary outcome (composite of hemorrhagic complications), but there was a trend (2.9% versus 4.5%, P=0.06) in favor of the ACTguided arm for ischemic events (death/MI/TVR). It seems that even in the modern era of NSTEMI PCI, patients with an ACT≤300 s are at increased risk of ischemic events. These data should inform both clinical practice and practice guidelines. In patients not receiving GP IIb/IIIa inhibitor therapy, the target ACT should be >300 s because we have demonstrated that it is associated with a lower risk of thrombotic complications without an increased risk of hemorrhagic complications.
Our analysis presents several limitations. First, the FUTURA/OASIS-8 trial enrolled only patients with NSTE-ACS and our observations cannot therefore be translated to STEMI or elective PCI. Second, the FUTURA/OASIS-8 Spline plot for logistic model adjusted for age, sex, diabetes mellitus, prior PCI, creatinine, systolic blood pressure, elevated biomarker at presentation, heart failure, and radial access. Median peak ACT (307 s) from all patients is the reference. Dashed lines indicate 95% confidence intervals. ACT Predicts Efficacy of UFH During PCI trial was powered for hemorrhagic outcomes; thrombotic outcomes were secondary outcomes. Third, this analysis was performed only in patients with ACT guided by the Hemochron device. Our results should not therefore be extrapolated to other devices. Fourth, we performed different types of analyses and only the threshold analysis was significant, analyses according to ACT categories and considering ACT as a linear function were negative. This could, however, be explained by the analysis of the curves showing that the relationship between ACT and both ischemic and bleeding complication is not linear. Finally, all patients received a low dose of fondaparinux before PCI, and our results might not be reproduced in patients receiving no or a different anticoagulant before undergoing PCI. To address those limitations and to increase the statistical power of our analysis, an external validation would be of interest.
Conclusions
In this analysis of the FUTURA/OASIS-8 trial, we observed that NSTE-ACS patients undergoing PCI with ACT<300 s may be at higher risk of thrombotic complications without a decrease in hemorrhagic complications. ACT did not, however, predict outcomes in patients receiving planned GP IIb/ IIIa inhibitors. These observations confirm the value of ACT guidance in modern NSTE-ACS PCI. †Lowest P value for death/myocardial infarction/target vessel revascularization=220 in patients without planned GP IIb/IIIa inhibitor use. 
